126 results
Page 3 of 7
8-K
EX-99.1
b1xprxvr jd6dseyqndb
6 Dec 22
Entry into a Material Definitive Agreement
9:25am
8-K
EX-99.1
rhs5xcwm6rssx q4m8f
22 Nov 22
VBI Vaccines Presents Additional Phase 1/2a Data from VBI-1901 in Recurrent GBM at the 2022 Society for Neuro-Oncology (SNO) Annual Meeting
8:00am
8-K
EX-99.1
p6ou bzi1na95ei7c
10 Nov 22
VBI Vaccines Reports Third Quarter 2022 Financial Results and Provides Corporate Update
8:00am
8-K
EX-99.1
q42951ksws vpls9
12 Oct 22
Regulation FD Disclosure
8:00am
8-K
EX-99.1
hpecwtdi
29 Sep 22
VBI Vaccines Announces Initiation of Phase 1 Study of Multivalent Coronavirus Vaccine Candidate, VBI-2901
8:00am
8-K
EX-99.1
x88h1 rg55wcm
21 Sep 22
Regulation FD Disclosure
8:10am
8-K
EX-99.1
at3wf0 3b
15 Sep 22
VBI Vaccines Secures $100 Million Debt Facility From K2 HealthVentures
5:01pm
8-K
EX-99.1
ljsq gp6h
8 Sep 22
Regulation FD Disclosure
6:10am
8-K
EX-99.1
er3ba0r1a8xbdxms
8 Aug 22
VBI Vaccines Reports Second Quarter 2022 Financial Results and Provides Corporate Update
8:01am
8-K
EX-99.1
1wq0c7zf0g0ob67wu9
12 Jul 22
VBI Vaccines Announces Appointment of John Dillman as Chief Commercial Officer
8:00am
8-K
EX-99.1
sojxox
28 Jun 22
VBI Vaccines Announces New Long-Term Follow-Up Clinical Data for its 3-Antigen Adult Hepatitis B Vaccine Presented at EASL 2022
8:00am
8-K
EX-99.1
4v6rl6d
22 Jun 22
VBI Vaccines Announces Results of Annual General Meeting
6:48pm
8-K
EX-99.1
gl7jrm5i14s 5v
22 Jun 22
VBI Vaccines Receives U.S. FDA Orphan Drug Designation for VBI-1901 for the Treatment of Glioblastoma
8:00am
8-K
EX-99.1
k98oznlcab 2uuwge
6 Jun 22
VBI Vaccines Presents Updated Phase 2a Tumor Response and Overall Survival Data for VBI-1901 in Recurrent GBM at the 2022 ASCO Annual Meeting
8:00am
8-K
EX-99.1
xdlwf9m
1 Jun 22
VBI Vaccines Announces UK MHRA Marketing Authorisation for PreHevbriâ„¢, a 3-Antigen
8:00am
8-K
EX-99.1
q2emyy hg
19 May 22
Regulation FD Disclosure
8:00am